A new survey published Tuesday showed a big jump in recent months in the number of companies considering "re-shoring" production from China, once favored for its low costs.
Boston Consulting Group said its survey found most large U.S. companies now plan to move some production to America from China, or are "actively considering" the move.
The number of firms that have shifted manufacturing to the U.S. from China, or will do so in the next two years, has nearly doubled over the past 18 months.
The survey found the three main drivers of the trend are labor costs, product quality and a desire to be closer to customers.
Best Energy Stocks To Buy For 2015: Idera Pharmaceuticals Inc.(IDRA)
Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer?s disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By John Udovich] Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:
��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, healthcare shares were relative leaders, up on the day by about 1.50 percent. Meanwhile, top gainers in the sector included Allergan (NYSE: AGN), up 15.7 percent, and Idera Pharmaceuticals (NASDAQ: IDRA), up 16.5 percent. Non-cyclical consumer goods & services shares dropped around 0.05 percent in today's trading. - [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]
Idera Pharmaceuticals Inc.(IDRA) said a recent clinical study of its plaque psoriasis treatment met its objectives, allowing the company to push forward with the treatment’s development. The company’s shares jumped 32% to $5.14 premarket.
- [By Roberto Pedone]
One under-$10 clinical stage biotechnology player that's starting to move within range of triggering a major breakout trade is Idera Pharmaceuticals (IDRA), which is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates. This stock has been on fire so far in 2013, with shares up huge by 221%.
If you take a look at the chart for Idera Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.55 to its intraday high of $3.10 a share. During that uptrend, shares of IDRA have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of IDRA within range of triggering a major breakout trade. In fact, shares of IDRA are ripping higher today by over 10% with strong upside volume as the stock moves close to entering breakout territory.
Traders should now look for long-biased trades in IDRA if it manages to break out above its 52-week high at $3.12 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 1.45 million shares. If that breakout triggers soon, then IDRA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $4 to $4.50 a share.
Traders can look to buy IDRA off any weakness to anticipate that breakout and simply use a stop that sits right below $2.50 a share, or near its 50-day at $2.22 a share. One can also buy IDRA off strength once it starts to take out $3.12 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best Stocks To Watch Right Now: Generale de Sante SA (GDS)
Generale de Sante SA, (also GDS), is a France-based provider of private hospital healthcare services. The Company offers a range of hospital services and, in partnership with independent medical specialists, delivers a spectrum of care services. Generale de Sante SA also provides services in the areas of mental health; oncology and radiation therapy; care for alcohol abuse and obesity; rehabilitation, such as cardiac rehabilitation and orthopedic and neurological reeducation, and diagnostics, such as medical imaging and analysis. It operates through one wholly owned subsidiary, CGS (Compagnie Generale de Sante). As of March 31, 2011, Sante Developpement Europe held a 54.47% stake in the Company�� shareholdings. Advisors' Opinion:- [By stanh30]
It does not matter if it�� a penny stock, all that matters is whether or not my reasoning is correct. However, in June the Global Depositary Shares (GDS) will undergo a 60:1 reverse split (pending shareholder approval) and the stock will no longer be a penny stock. Unfortunately the reverse split will occur after the June 12, 2014 record date for determining the persons and/or entities liable to the Depositary for the annual fee of $0.02 per Global Depositary shares for depositary services. This is an enormous fee for GDS shares, but one that I will pay due to the extreme undervaluation. Just remember that if you purchase the GDS shares on or before June 12th you are effectively paying an extra $0.02 per share.
5 Best Stocks To Watch Right Now: SunPower Corp (SPWR)
SunPower Corporation, incorporated in April 1985, is a vertically integrated solar products and services company that designs, manufactures and delivers solar electric systems worldwide for residential, commercial, and utility-scale power plant customers. The Company operates in two business segments: the Utility and Power Plants (UPP) Segment and the Residential and Commercial (R&C) Segment. The UPP Segment refers to its solar products and systems business, which includes power plant project development and project sales, turn-key engineering, procurement and construction (EPC) services for power plant construction, and power plant operations and maintenance (O&M) services. UPP Segment also sells components, including huge volume of sales of solar panels and mounting systems to third parties, sometimes on a multi-year, firm commitment basis. The R&C Segment focuses on solar equipment sales into the residential and small commercial market through its third-party global dealer network, as well as direct sales and EPC and O&M services in the United States and Europe for rooftop and ground-mounted solar power systems for the new homes, commercial and public sectors. In May 2012, K Road Power Holdings, LLC (K Road) and SunPower Corp announced that K Road acquired the 25-megawatt (AC) McHenry Solar Project, which the Company designed. In January 2013, the Company MidAmerican Solar acquired the 579-megawatt Antelope Valley Solar Projects (AVSP), two co-located projects in Kern and Los Angeles Counties in Calif from SunPower.
In January 2012, the Company completed its acquisition of the wholly owned Total SA subsidiary Tenesol SA, a global solar provider. In September 2011, NRG Energy Inc. acquired 250 megawatt California Valley Solar Ranch (CVSR) project from SunPower. In June 2011, the Company introduced SunPower E20 Series Solar Panel (E20) series. The Company�� customers in its UPP Segment include investors, financial institutions, project developers, electric utilities, and independent po! wer producers in the United States, Europe, and Asia. In its R&C Segment, the Company primarily sells its products to commercial and governmental entities, production home builders, and its third-party global dealer network serving residential owners and small commercial building owners.
Solar Cells
The A-300 solar cell is a silicon solar cell with a specified power value of 3.1 watts and a conversion efficiency averaging between 20.0% and 21.5%. The Company�� A-330 solar cell delivers 3.3 watts with a conversion efficiency of up to 22.7%.
Solar Panels
The Company�� SunPower solar panel series include solutions, such as SunPower E18 Series Solar Panel (E18), SunPower E19 Series Solar Panel (E19), and SunPower E20 Series Solar Panel (E20). Available in a 72-cell configuration, the E18 series panel uses its A300 all back-contact solar cells and delivers a total panel conversion of 18.1% to 18.5%. Available in a 72, 96, and 128-cell configuration, the E19 series panel uses its A300 all back-contact solar cells and delivers total panel conversion of 19.3% to 19.7%. Available in a 96-cell configuration, the E20 series panel uses its A-330 all back-contact solar cells and delivers total panel conversion of up to 20.1%.
Inverters
The Company sells a line of SunPower branded inverters. The inverters are manufactured by third parties.
Roof Mounted Products
The roof mounted products include SunPower T-5 Solar Roof Tile System (T-5), SunPower T-10 Commercial Solar Roof Tiles (T-10), PowerGuard Roof System (PowerGuard) and SunTile Roof Integrated System (SunTile). Tilted at a 5-degree angle, the T-5 roof tile is a non-penetrating photovoltaic rooftop product that combines solar panel, frame, and mounting system. The T-5 solar roof tile systems are primarily sold through its R&C Segment.
Tilted at a 10-degree angle, the T-10 commercial solar roof tiles is a non-penetrating panel interlock system! . Dependi! ng on geographical location and local climate conditions, this can allow for the generation of up to 10% more annual energy output than traditional flat roof-mounted systems. The T-10 commercial solar roof tile is primarily sold through its R&C Segment.
PowerGuard is a non-penetrating roof-mounted solar panel that delivers electricity while insulating and protecting the roof membrane from ultraviolet rays and thermal degradation. The PowerGuard roof system is primarily sold through its R&C Segment. SunTile solar shingles are designed to replace multiple types of roof panels, including the common concrete flat, low and high profile S tile and composition shingles. The SunTile roof system is also sold through its R&C Segment.
Ground Mounted Products
The ground mounted products include SunPower T-0 Tracker (T-0) & SunPower T-20 Tracker (T-20), SunPower Oasis Power Plant (SunPower Oasis), SunPower C-7 Tracker (C-7), and Fixed Tilt and SunPower Tracker Systems for Parking Structures. The T-0 and T-20 trackers are single-axis tracking systems that automatically pivot solar panels to track the sun's movement throughout the day. This tracking feature increases the amount of sunlight that is captured and converted into energy by up to 30% over flat or fixed-tilt systems, depending on geographic location and local climate conditions. A single motor and drive mechanism can control 10 to 20 rows, or more than 200 kilo watts of solar panels. The T-0 and T-20 trackers have been installed in a range of geographical markets principally in the United States, Germany, Italy, Portugal, South Korea, and Spain. The T-0 and T-20 trackers are sold through both its UPP and R&C Segments.
The Oasis is a solar power block that scales from 1 mega watts distributed installations to central station power plants. Oasis provides a way to deploy utility-scale solar power systems, streaming the development and construction process while optimizing the use of available land. The SunPow! er Oasis ! is sold through its UPP Segment. The C-7 combines a horizontal single-axis tracker with rows of parabolic mirrors, reflecting light onto linear arrays of its solar cells. The C-7 tracker is sold through its UPP Segment. SunPower has developed designs for solar power systems for parking structures in multiple configurations. These dual-use systems typically incorporate solar panels into the roof of a carport or similar structure to deliver onsite solar power while providing shade and protection. They are suited for parking lots adjacent to facilities. Fixed Tilt and SunPower Tracker Systems for parking structures are sold through both its UPP and R&C Segments.
Other System Offerings
SunPower�� metal roof system is designed for sloped-metal roof buildings, which are used in some winery and warehouse applications. This solar power system is designed for rapid installation. It also offers other architectural products, such as day lighting with translucent solar panels.
Balance of System Components
Balance of system components are components of a solar power system other than the solar panels. It includes SunPower branded inverters, mounting structures, charge controllers, grid interconnection equipment, and other devices depending on the specific requirements of a particular system and project.
The Company competes with Canadian Solar Inc., JA Solar Holdings Co., Kyocera Corporation, Mitsubishi Corporation, Q-Cells AG, Sanyo Corporation, Sharp Corporation, SolarCity Corporation, SolarWorld AG, Sungevity, Inc., SunRun, Inc., Suntech Power Holdings Co. Ltd., Trina Solar Ltd., Yingli Green Energy Holding Co. Ltd., Abengoa Solar S.A., Acconia Energia S.A., AES Solar Energy Ltd., Chevron Energy Solutions, EDF Energy plc, First Solar Inc., NextEra Energy, Inc., OPDE Group, NRG Energy, Inc., Recurrent Energy, Sempra Energy, Skyline Solar, Inc., Solargen Energy, Inc., Solaria Corporation, SolFocus, Inc., SunEdison and Tenaska, Inc.
Advisors' Opinion:- [By Travis Hoium and Erin Miller]
SunPower's (NASDAQ: SPWR ) higher guidance has investors excited about solar stocks again, and even Chinese companies have dreams of making a profit. It's been a long road back for investors in solar stocks, but the clouds are lifting. With financial performance improving at leaders First Solar (NASDAQ: FSLR ) and SunPower it may be time to get into the market. The Motley Fool's Erin Miller sat down with Fool.com contributor Travis Hoium to get the latest on the industry.
- [By Doug Ehrman]
On that front, Sun Power (NASDAQ: SPWR ) announced earlier this week that it was releasing its X-Series panels that are capable of achieving 21.5% efficiency. This level of efficiency puts the company in the industry-leading role and is probably one of the catalysts for First Solar's acquisition of TetraSun -- the company has achieved 21% efficiency in past projects. The flurry of good news provides solid evidence that solar energy is becoming increasingly viable and should aid in the U.S. push for energy independence.
- [By Travis Hoium]
What: Shares of First Solar (NASDAQ: FSLR ) dropped as much as 10% today, dragging the rest of the industry down with it. SolarCity (NASDAQ: SCTY ) dropped as much as 11% and SunPower (NASDAQ: SPWR ) fell 7% in early trading.
5 Best Stocks To Watch Right Now: JAKKS Pacific Inc.(JAKK)
JAKKS Pacific, Inc. designs, produces, markets, and distributes toys and consumer products worldwide. The company offers traditional toys and electronics, such as action figures and accessories, including licensed characters under Pokemon name; toy vehicles and accessories under Road Champs, Fly Wheels, and MXS names; electronics products under EyeClops Bionic Eye, Laser Challenge, and Plug It In & Play TV Games names; dolls and accessories, including small and large dolls, fashion dolls, and baby dolls under Disney Princess, Disney Fairies, Cabbage Patch Kids, Taylor Swift, Fancy Nancy, Hello Kitty, Graco, and Fisher Price names; private label products; pet products, including toys, consumables, and accessories under American Kennel Club and The Cat Fanciers? Association; and vehicles, play sets, plush products, construction toys, and infant and pre-school toys. It also offers role play, novelty, and seasonal toys, including food play and activity kits under Girl Gourmet, Creepy Crawlers, and BloPens names; role-play, dress-up, pretend play, and novelty products for boys and girls under Black & Decker, McDonald?s, Dirt Devil, Disney Princess, Disney Fairies, Barbie, and Dora the Explorer names; indoor and outdoor kids? furniture, activity trays, tables and room d Advisors' Opinion:
- [By Sean Williams]
JAKKS Pacific (NASDAQ: JAKK ) shares, for instance, were massacred last week after it lowered its full-year sales guidance by more than 10%, revised its full-year forecast from a modest profit to a hefty loss, and suspended its quarterly dividend indefinitely. Without its Pokemon licensing, JAKKS is struggling to find new sources of revenue growth.
- [By Peter Graham]
The Q3 2014 earnings report for large cap toy stock Mattel, Inc (NASDAQ: MAT), a potential peer of mid cap�Hasbro, Inc (NASDAQ: HAS) and small cap JAKKS Pacific, Inc (NASDAQ: JAKK), is scheduled for before the market opens on Thursday (October 16th). Aside from the Mattel, Inc earnings report, it should be said that Hasbro, Inc will report Q3 2014 earnings on October 20th (Next Monday)�before the market opens while�JAKKS Pacific, Inc will report Q3 2014 earnings before the market opens on October 23rd (Thursday). Mattel, Inc, like other toy stocks, has struggled to remain relevant in an age when many kids prefer to play video, mobile and computer games rather than with physical toys.
- [By Peter Graham]
The Q3 2014 earnings report for small cap toy stock JAKKS Pacific, Inc (NASDAQ: JAKK), a peer of toy stocks like Hasbro, Inc (NASDAQ: HAS) and Mattel, Inc (NASDAQ: MAT), is scheduled for before the market opens on Thursday (October 21st). Aside from the JAKKS Pacific earnings report, it should be said that Hasbro, Inc reported Q3 2014 earnings�yesterday (profit jumped 43% on higher international sales and strong demand for boys'�toys such as Transformers and Marvel products) while Mattel, Inc reported�Q3 2014 earnings on October 16th (Barbie sales�sank 21%, dragging sales down 8% and profit down 22%). Given those earnings reports along with the fact that JAKKS Pacific is the fourth most shorted stock on the NASDAQ with short interest of 52.31% (according to HighShortInterest.com), investors and the shorts alike will be paying close attention to what is reported.
- [By Patricio Kehoe] be receiving a $75 million senior secured credit facility. The financial help, directed towards corporate purposes and capital expenditures should be of great help to the toy designer and manufacturer, since 2013 was a rough year on earnings, and cash flow hit a historical low point with losses of over $32 million. However, the company seems confident it can turn results around and following management�� optimistic claim about 2014, several investment gurus like Paul Tudor Jones (Trades, Portfolio) and Jim Simons (Trades, Portfolio) hedge fund have bought JAKKS stock. So, let�� see what this toy designer has in store for the future.
Will 2013�� Challenges Be This year�� upside?
JAKKS hasn�� had the best of luck when it comes to product launches and financial earnings in the past, and the current anaemic economic situation has put yet another strain on consumer spending in the U.S. and Europe. But 2014 might be the growth year this toy manufacturer has been waiting for. After 2012�� row of acquisitions, including Maui Inc. (July 2012), JKID Ltd. (September 2012), a joint venture with NantWorks LLC to develop technologically orientated toys, and a 50% joint venture with the Japanese animation production firm, Pacific Animation Partners, has helped the firm gain significant brand strength, which should help boost top and bottom line growth. The most recent expansion of the Daniel Tiger�� Neighborhood franchise, which has been very successful since its holiday season launch and will now be available at Target Corp. (TGT), Kmart and Barnes & Noble Inc. (BKS), should also contribute to sales growth.
Moreover, the company�� product launches throughout 2013 improved substantially, with Disguise�� new Halloween costumes, kids��furniture, Tollytots infant and preschool products, Outdoor Engineer Sports products and Maui Toys��Impulse line driving sales. The recent integration of technology and novelty in its product launches, via Dre
No comments:
Post a Comment